Zacks Research Comments on AbbVie's Q1 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV - Free Report) - Investment analysts at Zacks Research cut their Q1 2025 earnings per share estimates for AbbVie in a research note issued on Wednesday, November 20th. Zacks Research analyst S. Ganoria now expects that the company will earn $2.62 per share for the quarter, down from their prior estimate of $2.67. The consensus estimate for AbbVie's current full-year earnings is $10.95 per share. Zacks Research also issued estimates for AbbVie's Q2 2025 earnings at $3.02 EPS, Q3 2025 earnings at $3.10 EPS, Q4 2025 earnings at $3.25 EPS, FY2025 earnings at $11.98 EPS, Q3 2026 earnings at $3.54 EPS and FY2026 earnings at $13.27 EPS.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.92 by $0.08. The business had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.95 earnings per share.

Several other equities analysts also recently weighed in on ABBV. Wells Fargo & Company raised their price target on AbbVie to $195.00 and gave the company a "buy" rating in a report on Tuesday. Wolfe Research began coverage on AbbVie in a report on Friday, November 15th. They set an "outperform" rating and a $205.00 price target for the company. UBS Group raised their price target on AbbVie from $195.00 to $200.00 and gave the company a "neutral" rating in a report on Thursday, October 31st. Citigroup reduced their price target on AbbVie from $226.00 to $215.00 and set a "buy" rating for the company in a report on Tuesday, November 12th. Finally, Guggenheim raised their price target on AbbVie from $212.00 to $221.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus price target of $203.50.

AbbVie Stock Up 3.0 %

Shares of NYSE:ABBV traded up $5.22 on Friday, hitting $176.95. 10,030,320 shares of the company traded hands, compared to its average volume of 5,514,954. AbbVie has a 52 week low of $137.65 and a 52 week high of $207.32. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The stock has a 50 day simple moving average of $189.81 and a 200-day simple moving average of $180.95. The company has a market cap of $312.70 billion, a PE ratio of 61.38, a PEG ratio of 2.03 and a beta of 0.63.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fairway Wealth LLC bought a new stake in AbbVie in the 2nd quarter worth approximately $26,000. Ridgewood Investments LLC bought a new stake in AbbVie in the 2nd quarter worth approximately $27,000. Groupama Asset Managment increased its stake in AbbVie by 40.3% in the 3rd quarter. Groupama Asset Managment now owns 135,749 shares of the company's stock worth $27,000 after acquiring an additional 38,974 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in AbbVie in the 3rd quarter worth approximately $28,000. Finally, Quest Partners LLC increased its stake in AbbVie by 4,140.0% in the 2nd quarter. Quest Partners LLC now owns 212 shares of the company's stock worth $36,000 after acquiring an additional 207 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.71%. The ex-dividend date is Wednesday, January 15th. This is an increase from AbbVie's previous quarterly dividend of $1.55. AbbVie's dividend payout ratio (DPR) is 215.28%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.